Was it worth the weight? - Drug review on two new weight loss agents: lorcaserin (Belviq®) and phentermine/topiramate ER (QsymiaTM)
| Autor: | Tiffany-Jade Kreys, Aaron Crawford |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Drug
Topiramate business.industry media_common.quotation_subject Pharmacology medicine.disease Obesity Phentermine/topiramate Lorcaserin Neuropsychology and Physiological Psychology Phentermine Anesthesia medicine Pharmacology (medical) Neurology (clinical) Dosing General Pharmacology Toxicology and Pharmaceutics Adverse effect business medicine.drug media_common |
| Zdroj: | Mental Health Clinician. 2:144-151 |
| ISSN: | 2168-9709 |
| DOI: | 10.9740/mhc.n129047 |
| Popis: | The prevalence of obesity in the United States (U.S.) is currently at 34%. This article will review two of the newer weight loss agents: lorcaserin and phentermine/topiramate. Mechanism of action, dosing, adverse events, and drug interactions will be discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|